[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,1075,0,25,[9,46,78,109,137,164,183,205,228,251,275,299,325,349,358,380,401,430,456,474,496,518,542,564,590],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053325","phase-1-facilitating-neuroplastic-changes-of-acute-stroke-survivors-100053325",false,"NCT06404268","Facilitating Neuroplastic Changes of Acute Stroke Survivors","Facilitating Neuroplastic Changes of Acute Stroke Survivors With Severe Hemiplegia","Inclusion Criteria:\n\n* Acute first time unilateral hemispheric stroke (hemorrhagic or ischemic stroke, 24 hours after admission to 1 month post-stroke at the start of the proposed treatment)\n* Hemiplegia or hemiparesis\n* 0≤Manual Muscle Testing (MMT)\\\u003C=2\n* Age 30-85\n* Ankle impairments including stiff calf muscles and\u002For inadequate dorsiflexion\n\nExclusion Criteria:\n\n* Medically not stable\n* Associated acute medical illness that interferes with ability to training and exercise\n* No impairment or very mild ankle impairment of ankle\n* Severe cardiovascular problems that interfere with ability to perform moderate movement exercises\n* Cognitive impairment or aphasia with inability to follow instructions\n* Severe pain in legs\n* Severe ankle contracture greater than 15° plantar flexion (when pushing ankle to dorsiflexion)\n* Pressure ulcer, recent surgical incision or active skin disease with open wounds present below knee","ALL","30 Years","85 Years",{"count":21,"type":22},68,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This project will develop a wearable rehabilitation robot suitable for in-bed acute stage rehabilitation. It involves robot-guided motor relearning, passive and active motor-sensory rehabilitation early in the acute stage post-stroke including patients who are paralyzed with no motor output. The early acute stroke rehabilitation device will be evaluated in this clinical trial.",[29],"Stroke",[29,31,32],"Paraplegia","Acute","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2025-07-01",{"date":41,"type":22},"2028-12-31",{"name":43,"class":44},"University of Maryland, Baltimore","OTHER",3,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100053705","screening-for-social-determinants-of-health-sdoh-and-cognitive-function-in-individuals-with-history-of-stroke-100053705","NCT06615973","Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke","Understanding Stroke Outcomes: Stroke Resilience, Infarct Burden, and Long-Term Cognition","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Adults aged 18 or older.\n* Previous participant in the Natural History of Stroke with an interpretable baseline MRI scan, NIHSS measured at baseline or discharge, and admission diagnosis of ischemic stroke.\n* Fluent in English or Spanish\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this\n\nstudy:\n\n-Modified Rankin Scale (mRS) = 6 at any follow-up (usually up to 90 days) in the Natural History of Stroke study (mRS = 6 indicates the participant is dead).","18 Years","99 Years",{"count":56,"type":22},450,"OBSERVATIONAL","Background:\n\nStroke is the fifth leading cause of death in the United States. It is also a leading cause of disability. More than 70% of people who survive strokes have mental impairment or dementia. Medical factors, such as the severity of the stroke, affect whether a person will have mental impairment afterward. But social factors, such as education and ethnicity, seem to play a role as well. Researchers want to learn more about how social and lifestyle factors affect a person s chances of maintaining mental functions after a stroke.\n\nObjective:\n\nTo better understand how social and lifestyle factors affect the risk of mental impairment after a stroke.\n\nEligibility:\n\nPeople aged 18 years and older who had a stroke and a brain scan while they were enrolled in NIH Study 01N0007 (Natural History of Stroke Study).\n\nDesign:\n\nParticipants will have 1 study visit, by telephone. The call will last about 45 minutes. Participants will talk about their health since their stroke. They will answer questions about themselves. Topics will include:\n\n* Their race\n* Education\n* Ethnicity\n* Employment\n* Marital status\n* Residence address\n* Recent health history\n* Medical insurance\n\nThey will have tests of their memory, attention, and language skills. They will repeat numbers and words forward and backward.\n\nResearchers will look at the data and imaging scans collected during participant s enrollment in NIH Study 01N0007. This data will include:\n\n* The hospital that first saw the participant at the time of their stroke.\n* The type of imaging that was first used then.\n* The primary diagnosis at admission.\n* Other medical details.",[29,60,61,62],"Brain Disease","Vascular Diseases","Cerebrovascular Disorder",[29,64,65,66,67,68],"Social Determinants of Health","Cognition","cerebrovascular health","Magnetic Resonance Imaging (MRI)","vascular health",{"date":36,"type":37},{"date":71,"type":22},"2026-07-16",{"date":73,"type":22},"2027-02-01",{"name":75,"class":76},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":77},"100053720","at-home-wearable-sensors-and-smartphone-for-stroke-survivors-with-upper-limb-motor-challenges-100053720","NCT06787729","At Home Wearable Sensors and Smartphone for Stroke Survivors With Upper Limb Motor Challenges.","Motivation-Induced Movement Therapy: Enhancing Upper Limb Engagement in Stroke Survivors Through Ring Sensors and Data Visualization.","Inclusion Criteria:\n\n* Stroke survivor (ischemic or hemorrhagic), \\>12 months post stroke, at the time of consent\n* Aged between 18 and 80\n* Ability to extend ≥ 10° at the metacarpophalangeal joint and one of the interphalangeal joints of each finger, ≥ 10° extension or abduction of the thumb, and ≥ 20° extension of the wrist from a fully flexed starting position.\n* Demonstrating more affected arm nonuse, defined as a MAL-AoU score of \\\u003C\u002F= 4.5.\n* Actively uses at least one smartphone app.\n* Strong beliefs towards being in control of their recovery, indicated by a score of ≤ 10 points on the Internal Recovery Locus of Control (I-RLOC) Scale.\n* Participants must be able to read, write, and understand English at a level sufficient to comprehend study materials and provide informed consent.\n\nExclusion Criteria:\n\n* Cognitive impairments that may affect the ability to understand and follow instructions (score \\\u003C 24 in the Mini Mental State Examination)\n* Difficulties comprehending numbers, dyslexia, severe aphasia, or other neurological conditions that prohibit the use of smartphones for safety reasons.\n* Undergoing other types of motor therapy during the study period.\n* Previous participation in constraint-induced movement therapy.\n* Currently participating in or has participated in the past 3 months in any experimental rehabilitation or drug studies.\n* Use of botulinum toxin for motor disability ≤ 3 months before treatment.\n* Significant changes in pharmacological or treatment plans during the study period that may affect upper-limb use.\n* Major medical problems that could interfere with participation.\n* History of a disabling stroke (i.e., need more than minimum assistance to perform ADLs).\n* Legally blind status.\n* Uncontrolled seizures.\n* Inability to don\u002Fdoff sensors independently or with the assistance of a caregiver.\n* Implantable medical devices that do not comply with the ISO 14117:2012 and\u002For ANSI\u002FAAMI PC69 standards for electromagnetic compatibility. Subjects will be asked to provide their medical device record card, and non-compliant devices will result in exclusion from the study.","80 Years",{"count":87,"type":22},50,[89],"NA","The goal of this clinical trial is to learn if wearable sensor data visualization on smartphones can improve the use of the stroke-affected limb during everyday activities. Chronic stroke survivors (\\>12 months from onset) ages 18-80 years old with residual upper extremity motor impairments may be eligible to participate. The main question it aims to answer is:\n\nDoes the mobile health (mHealth) intervention help to improve the use of the stroke-affected upper-limb during daily living?\n\nThe study is designed so each participant serves as their own control. Researchers will compare information from the baseline and intervention time periods to see if visualizing the data on the smartphone impacts the participant's daily use of the arm.\n\nParticipants will be asked to wear a set of wearable ring and wrist sensors and interact with a custom-designed smartphone app, aiming to increase the use of their stroke-affected limb during daily activities as much as possible. They will receive feedback from the app, communicate with study therapists, participate in goal setting, complete clinical assessments, and share about their experience using the system during a virtual interview.",[29],[93,94,95,96,97,98,99,100,29,101],"Hemiparesis","Upper extremity","Weakness","Arm","Hand","Ring Sensor","Wrist Sensor","mHealth","Activities of daily living",{"date":36,"type":37},{"date":104,"type":37},"2026-04-20",{"date":106,"type":22},"2027-07-31",{"name":108,"class":44},"Spaulding Rehabilitation Hospital",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":17,"minAge":53,"maxAge":19,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":77},"100053795","language-processing-and-tms-100053795","NCT05425615","Language Processing and TMS","Probing Language Processes Using Transcranial Magnetic Stimulation","Inclusion Criteria:\n\n* Diagnosed with left hemisphere stroke\n* Consent date \\>= 1 month after stroke onset\n* Right-handed\n* Fluent in English\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Severe cognitive, auditory or visual impairments that would preclude cognitive and language testing\n* Non-decisional per decisionality questionnaire or other clinical assessment\n* Presence of major untreated or unstable psychiatric disease (e.g. schizophrenia, bipolar disease)\n* A chronic medical condition that is not treated or is unstable\n* Presence of\n\n  1. cardiac stimulators or pacemakers or intracardiac lines\n  2. neurostimulators\n  3. medication infusion device\n  4. any other implants near the scalp (e.g., cochlear implants) or in the eye\n  5. metal in the body\n* Pregnancy\n* History of skull fractures, or skin diseases\n* History of ongoing or unmanaged seizures or a family history of epilepsy\n* Presence of factors that potentially decrease seizure thresholds\n* On pro-convulsant medications\n* Untreated Sleep deprivation or insomnia\n* Ongoing alcoholism or illegal drug abuse (e.g., cocaine or MDMA users)\n* History of dyslexia or other developmental learning disabilities",true,{"count":118,"type":22},135,[89],"This study will examine the effect of TMS on people with stroke and aphasia as well as healthy individuals.",[29,122,123],"Aphasia","Language",[125,126,122,127,128],"TMS","Transcranial Magnetic Stimulation","Semantic processing","Phonological processing","2026-07-09",{"date":36,"type":37},{"date":132,"type":37},"2024-06-05",{"date":134,"type":22},"2032-06",{"name":136,"class":44},"Medical College of Wisconsin",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":19,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":77},"100053876","environmental-perturbation-balance-training-improves-functional-outcomes-in-patients-with-subacute-stroke-100053876","NCT07697794","Environmental-perturbation Balance Training Improves Functional Outcomes in Patients With Subacute Stroke","Environmental-Perturbation Balance Training Improves Functional Outcomes in Patients With Subacute Stroke: A Prospective Randomized Controlled Trial","E-PBT","Inclusion Criteria:\n\nDiagnosed with stroke according to the International Symposium on Cerebral Vascular Disease criteria, with definite confirmation by imaging modalities such as computed tomography (CT) or magnetic resonance imaging (MRI).\n\nFirst-ever or recurrent cerebral hemorrhage or cerebral infarction. According to the Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association\u002FAmerican Stroke Association\\[11\\] and the Chinese Guidelines for Early Rehabilitation of Stroke\\[12\\], rehabilitation can be initiated once the patient's condition is stable (vital signs are stable and no further progression of symptoms and signs).\n\nTotal NIHSS score between 5 and 20 (inclusive) prior to randomization, with a lower limb motor score ≥2.\n\nPresence of balance dysfunction, with a miniBESTest total score ≤12. Good compliance with rehabilitation therapy and no contraindications to active training.\n\nAge between 18 and 85 years. The subject or their legal representative is able and willing to provide written informed consent.\n\nExclusion Criteria:\n\nHistory of prior cerebral hemorrhage or cerebral infarction with residual significant limb dysfunction.\n\nSevere cognitive impairment or sensory aphasia that precludes communication and cooperation with treatment.\n\nConcomitant severe cardiopulmonary, hepatic, or renal insufficiency, or other serious medical diseases.\n\nPresence of neurological or musculoskeletal disorders affecting balance function prior to stroke onset.\n\nUncontrolled severe hypertension or diabetes mellitus. Active bleeding or deep vein thrombosis. Current participation in another clinical trial or rehabilitation program that may affect the results of this study.\n\nAny other condition that may interfere with the outcomes of this study. History of limb amputation affecting bilateral coordination or independent walking ability.\n\nPregnancy.",{"count":146,"type":22},148,[89],"This study innovatively proposes an \"environment-perturbation balance training (E-PBT)\" intervention, which delivers stable, graded environmental perturbations to keep the challenges within the manageable range. This approach can significantly reduce fear, align with the psychological characteristics of subacute stroke patients, and improve training engagement and safety, thereby filling the current research gap that has insufficiently addressed subacute patients and those with moderate-to-low functional levels. By altering the size and angle of the support surface, this training heightens patients' alertness and psychological adaptability, prompting them to actively integrate sensory information and adjust motor strategies. In turn, this can more effectively reshape internal model of balance control and facilitate genuine neuroadaptive learning in the brain. Moreover, this training more closely mimics real-life fall scenarios, with the aim of directly cultivating the proactive postural control and strategic decision-making abilities required in daily living.\n\nThis study aims to systematically evaluate the efficacy of this E-PBT intervention on functional recovery in patients during the subacute stage of stroke through a prospective randomized controlled trial, and to explore its potential effects on balance ability, activities of daily living, and overall functional outcomes, thereby providing a more effective and clinically translatable new strategy for post-stroke rehabilitation.",[29],[29,151,152,153,154,155],"Subacute stage","Functional prognosis","Environment-perturbation balance training","Randomized controlled trial","Modified Rankin Scale","NOT_YET_RECRUITING",{"date":36,"type":37},{"date":159,"type":22},"2026-07-20",{"date":161,"type":22},"2027-12-01",{"name":163,"class":44},"First People's Hospital of Shenyang",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100053890","an-augmented-reality-based-system-for-neglect-detection-assessment-and-rehabilitation-100053890","NCT04187131","An Augmented Reality Based System for Neglect Detection, Assessment, and Rehabilitation","Inclusion Criteria:\n\n* ages18 and older\n* acute stroke\n* admitted to inpatient rehabilitation\n* presence of neglect (Behavioral Inattention Test total score \\\u003C129, or scoring below pre-defined cutoff score in at least one of the six subtests)\n* more than 10\u002F% missed targets on the Augmented Reality Screening Test\n* intact vibration (positive test on Vibration Sensation Test)\n* intact auditory function (positive test on Auditory Sensation Test)\n* English speaking\n\nExclusion Criteria:\n\n* inability to follow one-step directions at least 80% of the time\n* current diagnosis of dementia, Parkinson's disease, multiple sclerosis, or space-occupying tumor\n* metal in the head that causes interference with the EEG system\n* self-report of previous positive photic stimulation test",{"count":171,"type":22},10,[89],"The aim of this phase is to examine the feasibility and acceptability of the Augmented Reality (AR)-based and electroencephalography (EEG)-based neglect detection and rehabilitation tool.",[29],{"date":36,"type":37},{"date":177,"type":37},"2023-06-01",{"date":179,"type":22},"2029-09-30",{"name":181,"class":44},"University of Pittsburgh",2,{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":116,"sex":17,"minAge":53,"maxAge":19,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":77},"100053811","transcranial-alternating-current-stimulation-tacs-in-aphasia-100053811","NCT04375722","Transcranial Alternating Current Stimulation (tACS) in Aphasia","Exogenous Tuning of Neural Oscillations as a Mode of Treatment in Post-stroke Aphasia","Inclusion Criteria:\n\nHealthy Controls\n\n* 18 years of age or older\n* Fluent in English\n* No history of neurological or psychiatric disorders\n\nStroke Patients\n\n* Diagnosed with post-stroke aphasia by referring physician\u002Fneuropsychologist\n* Consent date \\>=1 months after stroke onset\n* Right-handed\n* Fluent in English\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Severe cognitive, auditory or visual impairments that would preclude cognitive and language testing\n* Presence of major untreated or unstable psychiatric disease\n* A chronic medical condition that is not treated or is unstable\n* The presence of cardiac stimulators or pacemakers\n* Any metal implants in the skull\n* Contraindications to MRI or tACS\n* History of seizures\n* History of dyslexia or other developmental learning disabilities",{"count":87,"type":22},[89],"This study will assess the effects of transcranial alternating current stimulation (tACS) on language recovery after stroke as well as healthy language functions.",[122,29],[195,196,197,198],"language","language impairment","transcranial alternating current stimulation","tACS",{"date":36,"type":37},{"date":201,"type":37},"2020-01-04",{"date":203,"type":22},"2030-12",{"name":136,"class":44},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":77},"100053736","effects-of-using-advanced-neurorehabilitation-technologies-in-upper-limb-motor-function-and-capacity-recovery-in-people-with-stroke-100053736","NCT07698405","Effects of Using Advanced NEUROrehabilitation TECHnologies in Upper Limb Motor Function and Capacity Recovery in People With Stroke","NEURO-TECH","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* First-ever unilateral ischemic or hemorrhagic stroke;\n* Presence of upper limb motor impairment;\n* Modified Ashworth Scale (MAS) \\\u003C 3;\n* Montreal Cognitive Assessment (MoCA) \\> 24;\n* Medically stable and able to participate in an intensive rehabilitation programme;\n* Ability to understand and follow study procedures;\n* Written informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of severe aphasia, based on medical records, preventing participation;\n* Bilateral hemisphere lesions;\n* Severe and unstable medical conditions (e.g. untreated seizure, heart failure) that preclude participation in rehabilitation;\n* Other neurological and\u002For psychiatric diseases;\n* Recent and unstabilized upper limb fracture.",{"count":7,"type":22},"This study aims to evaluate the effect of a personalized technology-based rehabilitative intervention on Upper Limb (UL) motor function and capacity recovery in People with Stroke (PwS). The study is single-cohort study in which eligible participants will undergo baseline and follow-up clinical and instrumental assessments over a 4-5 week period.\n\nThe intervention consists of a personalized and specific upper limb technology-based rehabilitation programme delivered three times per week for a total of 12-15 sessions. Each session lasts approximately one hour and is integrated with conventional rehabilitation treatments.\n\nPrimary outcomes include Fugl-Meyer Assessment for Upper Extremity (FMA-UE) and Action Research Arm Test (ARAT). Secondary outcomes include instrumental assessment of active range of motion and grip strength.",[29],[29,216,217,218,219],"Technology-Assisted Rehabilitation","Robotics","Virtual Reality","Motor Recovery","2026-07-07",{"date":36,"type":37},{"date":223,"type":37},"2026-06-15",{"date":225,"type":22},"2027-08",{"name":227,"class":44},"Azienda Unita Sanitaria Locale di Piacenza",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":234,"targetDuration":4,"studyType":23,"phases":236,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":77},"100053905","digital-technology-informed-stroke-rehabilitation-100053905","NCT07698522","Digital Technology-Informed Stroke Rehabilitation","Inclusion Criteria:\n\n* Age between 30-85 years.\n* Diagnosis of stroke.\n* Stroke onset of at least six months prior to the time of participation.\n* Fugl Meyer Upper Extremity between 30-50 (mild-moderate)\n* Cognitive skills to consent and actively participate, as indicated by scores of ≥ 24 on the Mini- Mental Status Examination\n* Able to visit lab up to 5x per week for 3 weeks\n\nExclusion Criteria:\n\n* Presence of severe aphasia preventing the ability to follow 1-step directions at least 80% of the time.\n* Excessive spasticity of the wrist, elbow, and shoulder, defined as a Modified Ashworth Score \\>2.\n* Diagnosis of neurological disorders other than stroke.\n* Orthopedic\u002Fmusculoskeletal conditions (e.g., severe arthritis) affecting the upper extremity.\n* Currently or planning to become pregnant.\n* Participation in concurrent occupational therapy.\n* Unilateral neglect, defined as failure of the Line Bisection Task\n* Upper extremity pain \\>= 7\u002F10 on Numeric Rating Scale",{"count":235,"type":22},60,[89],"The goal of this study is to determine the effects of lab and home-based technology guidance during movement training post-stroke. The study will compare movement training informed by lab-based technology to training delivered with technology at home. The main questions it aims to answer are:\n\n* How well do lab and home-based technologies help individuals post-stroke improve their movement patterns?\n* Is there a difference in improvement between the in-lab and at-home training groups?\n* Which technologies lead to the most improvement?",[29],[240,241,242],"movement training","rehabilitation","occupational therapy","2026-07-06",{"date":36,"type":37},{"date":246,"type":22},"2026-07",{"date":248,"type":22},"2033-12",{"name":250,"class":44},"University of Utah",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":258,"targetDuration":259,"studyType":57,"phases":4,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":77},"100643875","interoception-in-stroke-100643875","NCT07669246","Interoception in Stroke","Association of Interoception With Somatosensory Function, Proprioception, and Balance in Patients With Hemiplegia","Inclusion Criteria:\n\n* Presence of hemiplegia due to a physician-diagnosed stroke,\n* At least 6 months have passed since the stroke,\n* Voluntary agreement to participate in the study.\n\nExclusion Criteria:\n\n* History of traumatic brain injury, brain tumor, meningitis, or secondary neurological disease,\n* Having experienced a cardiovascular event or any acute medical condition within the last 3 months,\n* Insufficient visual or auditory ability to understand the questionnaires and tests.",{"count":235,"type":22},"1 Day","This study aims to examine the associations of interoceptive awareness and interoceptive accuracy with plantar superficial sensory threshold, knee joint proprioception, pain intensity, and dynamic balance performance in cognitively intact individuals with chronic hemiplegia.\n\nHypotheses are:\n\n* H0: There is no significant relationship between interoception and light touch, proprioception, pain, or dynamic balance performance in cognitively intact individuals with chronic hemiplegia.\n* H1: There is a significant relationship between interoception and light touch, proprioception, pain, or dynamic balance performance in cognitively intact individuals with chronic hemiplegia All participants will undergo a single assessment session and will not be invited for any treatment or follow-up evaluation. Participants will not take any intervention.",[29],[263,264,265],"Plantar sensation","Joint position sense","Fear of falling","2026-07-01",{"date":268,"type":37},"2026-07-02",{"date":270,"type":22},"2026-06-20",{"date":272,"type":22},"2026-12-25",{"name":274,"class":44},"Istinye University",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":295,"leadSponsor":297,"locationsCount":77},"100644637","effect-of-cerebellar-fastigial-nucleus-stimulation-combined-with-sling-exercise-on-motor-function-in-hemiplegic-stroke-patients-100644637","NCT07670936","Effect of Cerebellar Fastigial Nucleus Stimulation Combined With Sling Exercise on Motor Function in Hemiplegic Stroke Patients","Effects of Cerebellar Fastigial Nucleus Electrical Stimulation Combined With Sling Exercise Therapy on Motor Function in Hemiplegic Patients After Stroke","Inclusion Criteria:\n\n1. Met the diagnostic criteria for cerebrovascular disease in Western medicine;\n2. Were conscious, with stable vital signs and emotional state;\n3. Were male or female, aged 18 to 70 years, with disease onset within the previous 6 months;\n4. Had no significant cognitive or auditory comprehension impairments, were able to understand and execute relevant instructions, and could cooperate with the completion of relevant rehabilitation assessments;\n5. Were informed about the study and had signed an informed consent form.\n\nExclusion Criteria:\n\n1. Presence of severe organ dysfunction involving the cardiovascular, pulmonary, liver, or renal systems;\n2. Severe joint diseases, incompletely healed fractures, or severe osteoporosis;\n3. History of psychiatric illness or severe cognitive, visual, or auditory comprehension impairments that would prevent cooperation with instructions;\n4. Concurrent vestibular dysfunction;\n5. Unstable vital signs;\n6. Patients requiring mechanical ventilation;\n7. Contraindications to FNS, such as a history of epilepsy or the presence of intracranial metal foreign bodies.","70 Years",{"count":284,"type":22},54,[89],"This study aims to investigate the rehabilitative effects and synergistic potential of combining Fastigial Nucleus Stimulation (FNS) with Sling Exercise Training (SET) on motor function in patients with post-stroke hemiplegia. Hemiplegia after stroke often results in unilateral motor impairment, balance dysfunction, and decreased proprioception. Although traditional rehabilitation methods can improve certain functions, they are often limited by insufficient central targeting and inadequate activation of deep core muscles, making it difficult to fundamentally repair damaged motor control circuits. FNS, as a non-invasive neuromodulation technique, can precisely target the fastigial nucleus-a critical hub for motor coordination and balance control-thereby modulating neuroplasticity and promoting regional cerebral blood flow to optimize cortical function. SET, on the other hand, utilizes an unstable sling system to efficiently activate deep core muscles (such as the transversus abdominis and multifidus), enhance proprioceptive input, and promote neural reorganization. Based on the concept of \"central regulation-peripheral enhancement,\" this study hypothesizes that the combination of FNS and SET can create a bidirectional intervention pathway, breaking the vicious cycle between central damage and peripheral dysfunction, and achieving a \"1+1\\>2\" therapeutic effect. This study employs a randomized, double-blind, sham-controlled design and plans to enroll 54 eligible patients with post-stroke hemiplegia (aged 18-70 years, within 6 months of onset). Participants will be randomly assigned to three groups: Group A (FNS + sham SET), Group B (sham FNS + SET), and Group C (FNS + SET). FNS will be delivered using high-precision electrodes placed over the bilateral mastoid regions, with a stimulation frequency of 180 Hz and an intensity of 2 mA (sham stimulation at 0.1 mA) for 20 minutes per session. SET will include supine and prone bridging exercises for 30 minutes per session, while sham SET involves suspension without active movement. All patients will be assessed before and after the intervention using the Berg Balance Scale, Fugl-Meyer Assessment, three-dimensional gait analysis, trunk control test, and proprioceptive measurement instruments. The sample size was calculated based on previous data for lower extremity Fugl-Meyer scores (effect size f = 0.502), with an estimated 20% dropout rate, resulting in a target of 54 participants. The innovation of this study lies in its first-time combination of FNS-a more targeted neuromodulation approach-with SET-a high-intensity sensorimotor integration training-and the use of sham controls to precisely quantify the individual contributions of each intervention and validate the synergistic effect of central-peripheral co-stimulation. Potential risks will be strictly managed: FNS may cause localized tingling or mild headache, which can be addressed by adjusting or pausing stimulation; SET will be conducted under the supervision of trained therapists with individualized intensity adjustments to prevent muscle soreness or falls. All adverse events will be documented and managed promptly. The findings of this study are expected to provide an effective, non-invasive central-peripheral synergistic rehabilitation strategy for post-stroke hemiplegia and offer evidence-based guidance for clinical practice and future research.",[29],[29,289,290,291,292],"Cerebellar Fastigial Nucleus Electrical Stimulation","Sling Exercise Therapy","Three-Dimensional Gait","Motor Function",{"date":268,"type":37},{"date":266,"type":22},{"date":296,"type":22},"2027-04-30",{"name":298,"class":44},"Shengjing Hospital",{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":85,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":77},"100600317","respark---brain-q-for-chronic-stroke-100600317","NCT07095920","RESPARK - Brain Q for Chronic Stroke","Frequency-tuned Electromagnetic Field Treatment to Facilitate Recovery of Patients With Chronic Stroke","Inclusion Criteria:\n\n1. Upper Extremity Fugl-Meyer Assessment score between 22-50 (inclusive) of impaired limb.\n2. Upper Extremity Fugl-Meyer Assessment score is within up to 3-point difference between Screening and Baseline visit.\n3. Age 18 to 80 years of age (inclusive).\n4. Stroke due to ischemia or to intracerebral hemorrhage.\n5. \\>6 months to 5 years from stroke onset.\n6. Box \\& Block Test score with affected arm is ≥1 block in 60 seconds.\n7. Able to sit with the investigational system for 40 consecutive minutes.\n8. Can follow a 3-step command, such as \"take the paper, fold it in half, and return it to me\", or a non-verbal equivalent.\n9. Willingness to participate in physical exercises during study intervention sessions.\n10. Availability of a relative or other caregiver that is able to participate in training and assist during treatment sessions at Brooks and home during the study duration.\n11. If female, not pregnant or breastfeeding or planning pregnancy during the study period.\n12. The subject is able to provide Informed consent.\n\nExclusion Criteria:\n\n1. Severe neglect impairment interfering with assessments or treatments.\n2. Severe depression, defined as Geriatric Depression Scale (GDS) Score \\>10\u002F15\n3. Presence of implanted or retained MR-incompatible devices or materials, or the presence of life-sustaining MR-compatible devices (e.g. pacemaker or internal cardiac defibrillator).\n4. Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years\n5. Botulinum toxin to the paretic arm: received in the prior 3 months OR expected before the 6-Month Visit\n6. Severe upper extremity spasticity, defined as presence of contracture or modified Ashworth Scale score ≥3 in either biceps or pectoralis\n7. Pre-existing neurological condition (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or physical limitation that would interfere significantly with the subject's participation in the study and\u002For confound neurological or functional evaluation.\n8. Significant visual disturbances, pre-existing or resulting from the index stroke, that cannot be corrected and that would interfere significantly with the subject's participation in the study and\u002For confound neurological or functional evaluation.\n9. Unstable serious illness\u002Fcondition (e.g., active cancer, severe heart failure, active major psychiatric condition) or life expectancy of less than 12 months.\n10. Alcohol abuse and\u002For illicit drug abuse in the past 6 months, which is likely to influence ability to fully participate in the trial.\n11. Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.\n12. Active participation in an upper extremity rehabilitation program provided by a licensed provider within 4 weeks from the screening visit and until the primary endpoint visit.\n13. Employee of the Sponsor.\n14. Prisoner.",{"count":7,"type":22},[89],"This trial tests a promising new intervention to promote post-stroke neural reorganization and functional recovery. The Q Therapeutic (BQ 3.0) is a wearable medical system that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. This trial is a prospective, single-arm, open-label, single center clinical trial designed to evaluate the safety, feasibility, and efficacy of the Q Therapeutic (BQ 3.0) System in the rehabilitation of people with chronic stroke.",[29,310,311],"Chronic Stroke Patients","Cerebrovascular Accident (CVA)",[313,314,315,241,316,317],"BrainQ","Electromagnetic Stimulation","upper extremity","exercise","mobility",{"date":268,"type":37},{"date":320,"type":37},"2025-08-27",{"date":322,"type":22},"2026-12",{"name":324,"class":44},"University of Florida",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":85,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":348},"100568530","telerehabilitation-in-the-home-after-stroke-100568530","NCT06682429","Telerehabilitation In The Home After Stroke","Telerehabilitation In The Home After Stroke: A Randomized, Controlled, Assessor-Blind Clinical Trial","TR-2","Inclusion Criteria:\n\n1. Age 18-80 years at the time of randomization\n2. The index stroke was radiologically verified, due to ischemia or intracerebral hemorrhage (ICH), and had time of onset 120±30 days prior to randomization\n3. The stroke caused upper extremity deficits as defined by Action Research Arm Test score 18-44 (out of 57) at Baseline Visit 1\n4. Box \\& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit 1\n5. Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit 1\n6. Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent)\n\nExclusion Criteria:\n\n1. A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures\n2. Unable or unwilling to perform study procedures\u002Ftherapy, or expectation of noncompliance with study procedures\u002Ftherapy, or expectation that subject cannot participate in all study visits\n3. A diagnosis (apart from the index stroke) that substantially affects paretic arm function\n4. Severe depression, defined as Geriatric Depression Scale Score \\>10\u002F15 at Baseline Visit 1\n5. Significant cognitive impairment, defined as Montreal Cognitive Assessment score \\\u003C22 \\[a lower score is permitted if due to aphasia and allowed by the site PI\\]\n6. Deficits in communication that interfere with reasonable study participation\n7. Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis\n8. Modified Rankin Scale score was \\>2 prior to the index stroke\n9. A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke\n10. Lacking visual acuity, with or without corrective lens, of 20\u002F50 or better in at least one eye\n11. Life expectancy \\\u003C 9 months\n12. Pregnant; women of child-bearing potential must have a negative pregnancy test\n13. Botulinum toxin to the paretic arm: received in the prior 3 months OR expected by the 8-Month Visit\n14. Concurrent enrollment in another therapy-based investigational study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study\n15. Subject lacks sufficient English or Spanish to comply with study procedures and TR instructions\n16. Expectation that subject will not have a single domicile address during the 6 weeks of therapy that is within 1.5-hr drive of the central study site \\[this can be waived at the discretion of the site PI\\]\n17. Contraindication to MRI\n18. On isolation precautions, e.g., due to active COVID-19",{"count":334,"type":22},202,[89],"The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone.\n\nPatients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: \\[1\\] TR and usual care; \\[2\\] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes\u002Fday of activities targeting arm function, 6 days a week for 6 weeks.",[29],[339,241,340],"stroke","telehealth",{"date":268,"type":37},{"date":343,"type":37},"2025-08-22",{"date":345,"type":22},"2030-06",{"name":347,"class":44},"University of California, Los Angeles",27,{"id":350,"slug":4,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":351,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":352,"keywords":353,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":356,"leadSponsor":357,"locationsCount":77},"100563423",{"count":56,"type":22},[29,60,61,62],[29,64,65,66,67,68],{"date":268,"type":37},{"date":220,"type":22},{"date":73,"type":22},{"name":75,"class":76},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":85,"enrollmentInfo":366,"targetDuration":4,"studyType":23,"phases":368,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":77},"100429766","sonification-techniques-for-gait-training-100429766","NCT04876339","Sonification Techniques for Gait Training","Sonification Techniques for Gait Training: a Pilot Multicentric Randomized Controlled Trial","SonicWalk","Inclusion criteria (stroke patients)\n\n* Age \\\u003C 80\n* Mini Mental State Examination \\> 24\n* Modified Rankin Scale: 1-3\n* Single hemisphere lesion\n* Stabilized disease (\\> 6 months after the acute event)\n* Impairment in gait parameters (e.g. velocity, perceived fatigue etc)\n* Motor independence during walking (without orthotic devices and aids) but with pathological pattern (spasticity level: Ashworth \\\u003C 2)\n\nInclusion criteria (patients with Parkinson's disease)\n\n* Age \\\u003C 80\n* Mini Mental State Examination \\> 24\n* Unified Parkinson Disease Rating Scale score (Parte III): \\\u003C 28\n* Stabilized disease and drug therapy\n* Altered gait patterns\n* Motor independence during walking (without orthotic devices and aids) but with pathological pattern\n\nInclusion criteria (patients with multiple sclerosis):\n\n* Age \\\u003C 60\n* Mini Mental State Examination \\> 24\n* Expanded Disability Status Scale score: 3-5\n* Stabilized disease in the last 6 months (without relapse or disability progression)\n* Altered gait patterns (i.e., careening, slowing down, spasticity: Ashworth \\\u003C 2, etc.)\n* Motor independence during walking\n\nExclusion Criteria (stroke patients)\n\n* Multiple or bilateral lesions\n* Neglect\n* Equinism\n* Spasticity: Ashworth \\>2\n* Structured (non-elastic) Achilles tendon retraction\n* Neurotoxin in the 3 months prior to the study\n* Baclofen introduced or modified in the week before the start of the study\n* Previous or concurrent diseases disabling the lower limb functions\n* Rehabilitative treatments with music in the year before the study\n\nExclusion criteria (patients with Parkinson's disease):\n\n* Previous or concurrent diseases disabling the lower limb functions\n* Changes of drug therapy during the study\n* Rehabilitative treatments with music in the year before the study\n\nExclusion criteria (patients with multiple sclerosis):\n\n* Previous or concurrent diseases disabling the lower limb functions\n* Neurotoxin in the 3 months prior to the study\n* Baclofen introduced or modified in the week before the start of the study\n* Spasticity: Ashworth \\>2\n* Structured (non-elastic) Achilles tendon retraction\n* Rehabilitative treatments with music in the year before the study",{"count":367,"type":22},120,[89],"Music therapy is widely used in relational and rehabilitation settings. In addition to Neurologic Music Therapy and other music-based techniques, \"sonification\" approaches were recently introduced in the field of rehabilitation. The \"sonification\" can be defined as a properly selected set of sonorous-music stimuli are associated with patient movements mapping. In fact, the auditory-motor feedback can replace damaged proprioceptive circuits with a consequent improvement of the rehabilitation process. Interventions with \"sonification\" facilitate sensorimotor learning, proprioception and movements planning and execution improving global motor parameters. This study proposes the use of musical auditory cues which includes the melodic-harmonic component of the music. This kind of sonification makes the feedback pleasant and predictable as well as potentially effective. The investigators propose to apply and assess the effectiveness of this kind of sonification on gait training and other secondary outcomes in stroke, Parkinson's disease and multiple sclerosis population. Also, the investigators will assess the impact of \"sonification\" on the level of fatigue perceived during the rehabilitation process and on the quality of life. The study is a multicenter randomized controlled trial and will involve 120 patients that will undergo standard motor rehabilitation or the same rehabilitation but with the sonification support. The interventions will be evaluated at the baseline, after 10 sessions, after 20 sessions and at follow-up (one month after the end of the treatment). The assessment will include functional, motor, fatigue and quality of life evaluations. The collected data will be statistically processed.",[371,29,372],"Parkinson Disease","Multiple Sclerosis",{"date":268,"type":37},{"date":375,"type":37},"2021-01-18",{"date":377,"type":22},"2027-06-30",{"name":379,"class":44},"Istituti Clinici Scientifici Maugeri SpA",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":390,"conditions":391,"keywords":392,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":399,"locationsCount":77},"100644977","overground-virtual-reality-vr-gait-rehabilitation-for-stroke-100644977","NCT07676578","Overground Virtual Reality (VR) Gait Rehabilitation for Stroke","Investigating the Feasibility and Translational Therapeutic Benefits of Overground, Fully Immersive Virtual Reality (VR) Gait Rehabilitation Therapies for Stroke Survivors","Inclusion Criteria:\n\n* Diagnosis: Anischemic or hemorrhagic stroke verified by imaging, confirmed by the patient's physician, and 1-6 months post-stroke (subacute phase)\n* Motor Impairment Level: Functional Ambulation Category (FAC) 3-5, showing moderate impairment while still allowing safe participation in gait tasks.\n* Cognitive Function: Mini-Mental State Examination (MMSE) score ≥ 24 or Montreal Cognitive Assessment (MoCA) score \\>= 20, indicating sufficient cognitive function to participate in the study.\n* Exercise Clearance: Approval from a physician for participation in exercise- and VR-based interventions.\n* Rehabilitation Need: 10-Meter Walk Test \\\u003C1.0 m\u002Fs, as timed by a PT during screening, indicating a need for functional rehabilitation.\n* Consent: Must be able to provide informed consent for themselves.\n\nExclusion Criteria:\n\n* Participants with uncontrolled cardiovascular, orthopedic, or metabolic conditions or unstable medication regimens that could interfere with their participation in the study.\n* Any comorbidity that could interfere with walking or gait training.\n* Participation in robot- or VR-assisted gait training within the last 6 months.\n* Intolerance to virtual reality environments or motion simulation.\n* Severe cognitive, visual, or hearing impairments where the participant cannot follow the therapist's instructions.\n* Any other condition deemed unsafe or confounding by investigator, such as pre-existing neurological conditions unrelated to stroke (e.g. Parkinson's, multiple sclerosis), unmanaged pain medications, or acute medical events during the screening period (e.g. recurrent stroke, hospitalization).\n* Individuals who score a 12 or higher on the Disability Rating Scale.\n* Recent Therapy: Participants should not have received physical therapy (PT) within the last month.",{"count":388,"type":22},30,[89],"The purpose of this study is to evaluate a new virtual reality (VR)-based rehabilitation program designed to help stroke survivors improve their walking abilities in real-world settings. By comparing immersive VR-assisted overground gait therapy to contemporary non-immersive, treadmill-based VR therapy (i.e., C-Mill), the investigators aim to determine its effectiveness in enhancing mobility and quality of life for stroke survivors.",[29],[393,218,29],"Gait Training","2026-06-29",{"date":266,"type":37},{"date":397,"type":22},"2026-08",{"date":225,"type":22},{"name":400,"class":44},"Indiana University",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":17,"minAge":409,"maxAge":85,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":411,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":182},"100627223","protecting-the-brain-from-post-stroke-cognitive-impairment-and-dementia-with-multimodal-exercise-training-100627223","NCT07445841","Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training","Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training: A Bayesian Adaptive Trial (PROTECT)","PROTECT","Inclusion Criteria:\n\n* have had a first-ever ischemic\u002Fhemorrhagic stroke confirmed by MRI\u002FCT 0-6 months prior to participation.\n* Able to independently walk at least 10 meters (assistive devices permitted) and capable of following instructions will be required.\n\nExclusion Criteria:\n\n* Diagnosed with dementia\n* Medications that impact cognition\n* Absolute contraindications to exercise or MRI scanning\n* Significant disability (modified Rankin score \\>3)\n* Participants will be excluded if they have been engaged in a structured exercise training program outside their regular in\u002Fout-patient hospital rehabilitation since suffering the stroke.\n* Co-morbidities that preclude exercise participation, pain worsened with exercise, and communication (e.g., severe aphasia) or behavioral issues limiting safe participation will also be reasons for exclusion.","40 Years",{"count":367,"type":22},[89],"The rates of cognitive decline and dementia after stroke are disproportionately high. Strategies that can protect the brain early after the stroke event could reduce the future risk of cognitive decline and dementia in these patients. Although physical exercise is usually recommended after stroke, there is very little information about the protective effect of exercise implemented in early stages of recovery as a potential protective measure against cognitive decline and dementia risk in these patients. This study will investigate the effect of a multimodal exercise intervention implemented early after the stroke event on cognition and on a selected group of markers that can predict cognitive decline and dementia risk.",[29],[415,416,417,418,419,420,421],"multimodal exercise","cognition","blood brain barrier permeability","cerebral blood flow","inflammation","neurodegeneration","subacute stroke","2026-06-28",{"date":266,"type":37},{"date":425,"type":37},"2026-03-09",{"date":427,"type":22},"2030-12-31",{"name":429,"class":44},"McGill University",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":436,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":438,"briefSummary":439,"conditions":440,"keywords":443,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":454,"locationsCount":77},"100642930","mobile-cognitive-behavioral-therapy-in-early-stroke-recovery-100642930","NCT07639606","Mobile Cognitive Behavioral Therapy in Early Stroke Recovery","Inclusion Criteria:\n\n* Age 18-79\n* Positive screen on the Hospital Anxiety and Depression Scale (HADS), either the HADSD (depression, score \\>= 8) and\u002For HADS-A (anxiety, score \\>= 8).\n* Stroke that occurred within 1 month prior to study initiation.\n* Capacity to provide consent as determined by the UCSD Brief Assessment for Capacity to Consent (UBACC)\n* Montreal Cognitive Assessment (MoCA) score greater than or equal to 18, indicating no more than mild cognitive difficulties\n* Ability to use iPhone or iPad independently or through the assistance of a caregiver (participants will use their own iPhone if they have one, otherwise they will be loaned an iPad by the study team)\n* Able to adhere to all study requirements and willingness to participate in the full study duration\n\nExclusion Criteria:\n\n* Aphasia or neglect that would interfere with use of the app, as determined through evaluation by speech-language pathology and occupational therapy conducted as part of standard clinical care\n* Non-fluency in English\n* History of a major neurologic disorder or of serious mental illness (bipolar or psychotic disorder, alcohol or substance use disorder as assessed through chart review)\n* Active suicidal ideation requiring a higher level of care\n* Severe depression and\u002For anxiety based on the initial evaluation and clinical judgment of the PI, which warrants a higher level of care and\u002For immediate referral to psychiatric services\n* Any other clinical or medical reason in the initial evaluation that suggests the study is not appropriate for the participant","79 Years",{"count":171,"type":22},[89],"This study aims to pilot \"Maya,\" a mobile cognitive behavioral therapy app, for use in adults with stroke experiencing depression and\u002For anxiety. This study will assess the acceptability, feasibility, and preliminary efficacy of Maya within the acute rehabilitation period.",[441,29,442],"Anxiety","Depression - Major Depressive Disorder",[444,445,446,447],"stroke recovery","stroke rehabilitation","cognitive behavioral therapy","CBT","2026-06-26",{"date":450,"type":37},"2026-06-30",{"date":246,"type":22},{"date":453,"type":22},"2029-03",{"name":455,"class":44},"Weill Medical College of Cornell University",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":23,"phases":465,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":471,"leadSponsor":472,"locationsCount":182},"100631423","pilot-study-home-use-of-wearable-grasping-neuroprosthesis-in-vascular-hemiparesis-100631423","NCT07500480","Pilot Study: Home Use of Wearable Grasping Neuroprosthesis in Vascular Hemiparesis","Pilot Study Evaluating the Usability and Functional Impact of Prolonged Home Use of a Wearable Grasping Neuroprosthesis in Subjects With Vascular Hemiparesis - GRASP-HOME","GRASP-HOME","Inclusion CriteriA\u002F\n\n* Adult patient who participated in and completed the GRASP-AGAIN study and achieved functional improvement through the use of NAP.\n* Motor deficit of an upper limb resulting from a single ischemic or hemorrhagic stroke, hemispheric or brainstem, confirmed by brain imaging (CT scan or MRI);\n* Brain lesion occurring more than one month prior;\n* Presence of at least one of the following two disabilities:\n\n  * Inability to actively extend the long fingers (open the hand) to actively grasp an empty glass (upper and lower diameters of 7 and 6 cm respectively, height of 12 to 15 cm, weight of 125 g, identical to the material used for the Action Research Arm Test scale) with a palmar grip, without the aid of the other hand, while the subject is able to hold the glass passively in the hand;\n  * Inability to actively extend the thumb to grasp the handle of a soup spoon (flat, like a key) without the aid of the other hand, using a thumb-index finger pulp-lateral grip (grasping task in the Wolf Motor Function Test), while the subject can passively hold the handle of a spoon or a key previously placed between the thumb and index finger;\n* Patient receiving care within the standard healthcare pathway;\n* Ability to sit in a chair and remain focused for at least 1.5 hours;\n* Free, informed, and written consent signed by the participant and the investigator (no later than the day of enrollment and before any examination required for the research);\n* Individual affiliated with or covered by a social security scheme\n\nExclusion Criteria:\n\n* The person is in labor or breastfeeding;\n* The person is pregnant, the diagnosis being guided by questioning (date of last menstrual period, desire for pregnancy, contraception) and possibly confirmed by a blood test for beta hCG;\n* Musculotendinous contractures or joint stiffness of the fingers and wrist preventing passive opening of the fingers;\n* Limited approach ability preventing the hand from being positioned in front of the abdomen (without contact) at the level of the midline sagittal plane, while the subject is seated;\n* Paretic pain in the upper limb limiting the performance of the standardized grasping task;\n* Major sensory disturbances corresponding to a Somatosensation subscore of the modified Erasmus Nottingham Sensory Assessment French version (EmNSA-F, see Appendix A) upper limb \\\u003C10\u002F44;\n* Severe aphasia with a Boston Diagnostic Severity Aphasia Examination Severity Scale score ≤ 3, see Appendix B, indicating that there may be a marked decrease in verbal fluency or ease and rapidity of comprehension, without significant limitation of expression or communication;\n* Known gestural apraxia, within the limits of the subject's motor abilities (ideomotor apraxia, ideational apraxia, dressing apraxia, or reflexive apraxia);\n* Unilateral spatial neglect demonstrated with the bell test (see Appendix B'), if the difference between omissions in the left and right visual fields is greater than or equal to 6;\n* The extensor digitorum communis and\u002For extensor pollicis longus muscles cannot be stimulated with the neuroprosthesis, meaning that sufficient extension of the long fingers and\u002For thumb for grasping tasks is not achieved with electrical stimulation well tolerated by the patient;\n* The person has a pacemaker;\n* Presence of uncontrolled epilepsy;\n* Presence of unstable cardiovascular disease (coronary artery disease, severe hypertension, heart failure);\n* Presence of a dermatological condition contraindicating the application of surface electrodes;\n* The person is participating in another research study with an ongoing exclusion period;\n* The person is under legal guardianship or conservatorship;\n* The person refuses to sign the consent form;\n* It proves impossible to provide the person with informed consent and ensure their compliance due to impaired physical and\u002For psychological health.",{"count":182,"type":22},[89],"Stroke is the leading cause of acquired motor disability in adults. Six months post-stroke, 50% of patients have not regained active finger extension, and 80% retain a grasping deficit, most commonly an inability to actively open the hand. This motor impairment significantly impacts daily activities, social interactions, professional life, and overall quality of life. Despite numerous treatments available in rehabilitation centers during the subacute phase, no functional assistive devices are currently usable at home. Since 2018, our team, in collaboration with the CAMIN-INRIA team, has developed a Grasp Neuroprosthesis (GNP). This device uses functional electrical stimulation to restore grasping function in hemiplegic subjects, enhancing autonomy in daily bimanual tasks. The GNP has been evaluated in hospital settings through two studies, defining preferred control modalities and demonstrating significant functional impact. Additionally, another study tested a wearable version of the GNP used autonomously at home for two months. This study showed the feasibility and functional benefits of home GNP use, provided the device is customizable to the patient's characteristics and environment. Initial results indicate improved quality of life and increased autonomy with GNP use. The wearable GNP consist of a forearm orthosis made of soft fabric, integrating an electrode array and a stimulator (CE medical marking for home use), connected via WiFi to a microprocessor positioned in a pouch. The microprocessor incorporates information from inertial measurement units and a microphone, allowing the user to control the electrical stimulator on demand. The stimulation targets the extensor muscles of the long fingers and the thumb, enabling the user to open the hand on demand. We propose extending the home use of the GNP to two patients for one year. Each subject will be followed for one year, with evaluations in a hospital setting at the beginning and end of the period, monthly follow-ups at home throughout the year, and on-demand video consultations.",[29,468],"Réhabilitation",{"date":450,"type":37},{"date":104,"type":37},{"date":296,"type":22},{"name":473,"class":44},"University Hospital, Toulouse",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":485,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":77},"100586741","effectiveness-of-the-cognitive-orientation-to-daily-occupational-performance-co-op-100586741","NCT06919315","Effectiveness of the Cognitive Orientation to Daily Occupational Performance (CO-OP)","Effectiveness of the Cognitive Orientation to Daily Occupational Performance (CO-OP) in a Danish Rehabilitation Context","Inclusion Criteria:\n\n* Stroke or traumatic brain injury\n* Reffered from acute hospital or specialized rehabilitation units to municipal rehabilitation\n* Having at least on ADL performance issue\n\nExclusion Criteria:\n\n* Dementia, Psychotic diagnoses, commotio, Brain tumor or degenerative neurological conditions.\n* Alkohol or drug abuse\n* Not speeking or understanding Danish",{"count":87,"type":22},[89],"The goal of this clinical study is to examine the effectiveness of the Cognitive Orientation to daily Occupational Performance (CO-OP) in adults (18+) with accuired brain injury when applied in Danish rehabilitation context. The primary research question is: What is the effectiveness of the CO-OP approach on improvement of performance of daily activities (ADL) and quality of life compared to usual rehabilitation practice.\n\nParticipants in the intervention group will recieve the CO-OP intervention as part of their rehabilitation in the following phases:\n\nInitial phase: Goalsetting is mandatory and based on the participant's prioritized ADL performance issues identified in their baseline COPM. Education phase: Individual education in the metacognitive Goal-Plan-Do-Check strategy. Training phase: CO-OP training that involves repetitive use of the Goal-Plan-Do-Check for problem solving and skill acquisition. The therapist employs dynamic performance analysis and guided discovery to help participants understand performance issues and formulate plans for achieving their goals. Participants then execute and evaluate these plans, with a focus on developing domain-specific cognitive strategies. The therapist actively encourages generalization and transfer of skills. Homework is mandatory.\n\nParticipants in the control group will recieve usual rehabilitation practice in the following phases:\n\nInitial phase: Goalsetting is optional and may be based on previous assessment or on a conversation with the participant. Training phase: Different approaches may be taken such as observation and practice of activities or consultation about performance issues and how participants may deal with them. The therapist may guide the participant's performance verbally, physically or trough picture materials. Homework may be included.",[29],[29,486,487,488],"Rehabilitation","CO-OP","Occupational Therapy",{"date":394,"type":37},{"date":491,"type":37},"2025-05-02",{"date":493,"type":22},"2027-07",{"name":495,"class":44},"Louise Møldrup Nielsen",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":517},"100450615","the-conform-pivotal-trial-100450615","NCT05147792","The CONFORM Pivotal Trial","An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left Atrial Appendage Occlusion","Inclusion Criteria:\n\n1. Male or non-pregnant female aged ≥18 years\n2. Documented non-valvular AF (paroxysmal, persistent, or permanent)\n3. High risk of stroke or systemic embolism, defined as CHA2DS2-VASc score of ≥ 3\n4. Has an appropriate rationale to seek a non-pharmacologic alternative to long-term oral anticoagulation\n5. Deemed by the site investigator to be suitable for short term oral anticoagulation therapy but deemed less favorable for long-term oral anticoagulation therapy.\n6. Deemed appropriate for LAA closure by the site investigator and a clinician not a part of the procedural team using a shared decision-making process in accordance with standard of care\n7. Able to comply with the protocol-specified medication regimen and follow-up evaluations\n8. The subject (or legally authorized representative, where allowed) has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate institutional review board (IRB)\u002FRegional Ethics Board (REB)\u002FEthics Committee (EC).\n\nExclusion Criteria:\n\n1. Pregnant or nursing patients and those who plan pregnancy in the period up to one year following the index procedure. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to index procedure.\n2. Anatomic conditions that would prevent performance of an LAA occlusion procedure (e.g., atrial septal defect (ASD) requiring closure, high-risk patent foramen ovale (PFO) requiring closure, a highly mobile inter-atrial septal aneurysm precluding a safe TSP, presence of a PFO\u002FASD closure device, history of surgical ASD repair or history of surgical LAAO closure)\n3. Atrial fibrillation that is defined by a single occurrence or that is transient or reversible (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)\n4. A medical condition (other than atrial fibrillation) that mandates long-term oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or prosthetic mechanical heart valve)\n5. History of bleeding diathesis or coagulopathy, or patients in whom antiplatelet and\u002For anticoagulant therapy is contraindicated\n6. Documented active systemic infection\n7. Symptomatic carotid artery disease (defined as \\>50% stenosis with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is \\\u003C50% stenosis noted at the site of prior treatment\n8. Recent (within 30 days of index procedure) or planned (within 60 days post-procedure) cardiac or major non-cardiac interventional or surgical procedure\n9. Recent (within 30 days of index procedure) stroke or transient ischemic attack\n10. Recent (within 30 days of index procedure) myocardial infarction\n11. Vascular access precluding delivery of implant with catheter-based system\n12. Severe heart failure (New York Heart Association Class IV)\n13. Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral valve intervention, or any prosthetic mechanical valve implant\n14. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2 (by the Modification of Diet in Renal Disease equation)\n15. Platelet count \\\u003C75,000 cells\u002Fmm3 or \\>700,000 cells\u002Fmm3, or white blood cell count \\\u003C3,000 cells\u002Fmm3\n16. Known allergy, hypersensitivity or contraindication to aspirin, heparin, or that would preclude any P2Y12 inhibitor therapy, or to device materials (e.g., nickel, titanium), or the subject has contrast sensitivity that cannot be adequately pre-medicated\n17. Actively enrolled or plans to enroll in a concurrent clinical study in which the active treatment arm may confound the results of this trial\n18. Unable to undergo general anesthesia\n19. Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 5 years\n20. A condition which precludes adequate transesophageal echocardiographic assessment\n\nEcho exclusion criteria:\n\n1. Left atrial appendage anatomy which cannot accommodate a commercially available control device or the CLAAS Implant per manufacturer IFU (e.g., the anatomy and sizing must be appropriate for both the investigational (CLAAS) and a commercially available device in order to be enrolled in the trial)\n2. Intracardiac thrombus or dense spontaneous echo contrast consistent with thrombus, as visualized by TEE\n3. Left ventricular ejection fraction (LVEF) \\\u003C30%\n4. Moderate or large pericardial effusion \\>10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology\n5. Atrial septal defect that warrants closure\n6. High risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (excursion \\>15 mm or length \\> 15 mm) or large shunt (early \\[within 3 beats\\] and\u002For substantial passage of bubbles, e.g., \\>20)\n7. Moderate or severe mitral valve stenosis (mitral valve area \\\u003C1.5 cm2)\n8. Complex atheroma with mobile plaque of the descending aorta and\u002For aortic arch\n9. Evidence of cardiac tumor",{"count":504,"type":22},1600,[89],"The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.",[508,29],"Atrial Fibrillation",{"date":394,"type":37},{"date":511,"type":37},"2022-05-26",{"date":513,"type":22},"2031-12",{"name":515,"class":516},"Conformal Medical, Inc","INDUSTRY",92,{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":525,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":531,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":77},"100644017","effectiveness-of-attention-focus-training-on-attention-and-quality-of-life-in-stroke-100644017","NCT07668245","Effectiveness of Attention Focus Training on Attention and Quality of Life in Stroke","AQoLStroke","Inclusion Criteria:\n\n* Participants diagnosed with stroke\n* Able to ambulate at least with assistance\n* Medically stable\n\nExclusion Criteria:\n\n* Severe cognitive impairment (MMSE \\\u003C 24)\n* Pre-existing dementia\n* Visual\u002Fhearing impairment","55 Years",{"count":527,"type":22},46,[89],"This RCT will determine the effects of attention focus training which is a comprehensive intervention to improve cognitive outcomes. Attention is one of the major cognitive outcome and problems with attention can deteriorate the quality of life of people suffering from stroke. Intervention will be provided for 4 weeks. Outcomes will be assessed at baseline and after provision of intervention.",[29],[532,533,29],"Attention","Quality of life","2026-06-25",{"date":450,"type":37},{"date":537,"type":22},"2026-07-03",{"date":539,"type":22},"2026-10-03",{"name":541,"class":44},"Shifa Tameer-e-Millat University",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":549,"enrollmentInfo":550,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":563},"100547053","clevidipine-for-the-antihypertensive-treatment-of-acute-intracerebral-hemorrhage-100547053","NCT06402968","Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage","CLUTCH","Inclusion Criteria\n\n1. Age 18 years or older and less than 100 years.\n2. Onset of new neurological deficits within 12 hours at the time of enrollment and IV clevidipine or alternate IV antihypertensive regimen can be initiated within 12 hours of symptom onset.\n3. Clinical signs consistent with the diagnosis of stroke, including impairment of language, motor function, cognition, and\u002For gaze, vision, or neglect.\n4. Initial National Institutes of Health Stroke Scale (NIHSS) score of 1 or greater.\n5. Total GCS score (aggregate of verbal, eye, and motor response scores) of 5 or greater at enrollment\n6. Computed Tomography (CT) scan of the brain demonstrates intraparenchymal hematoma with manual hematoma volume measurement \\>5 cc (excluding microhemorrhages)\n7. Admission SBP greater than and equal to 150 mmHg but less than 220 mmHg on two repeat measurements at least 5 minutes apart, but no more than 10 minutes apart. The reason for exclusion of ICH patients with initial SBP ≥220 mm Hg is based on a post hoc analysis of ATACH-2, which found that patients with initial SBP ≥220 mm Hg (22.8% of the cohort) reported higher rates of neurological deterioration at 24 hours and renal adverse events until day 7 or discharge in patients treated with intensive SBP reduction compared with standard SBP lowering, without any benefit in reducing hematoma expansion at 24 hours or death or severe disability at 90 days.\n8. Signed and dated informed consent by subject, legally authorized representative, or surrogate before index hospital discharge for data collection and agreement to participate in 90- and 180-day follow-up visits.\n9. Patients with anticoagulant-related ICH are eligible as long as anticoagulant reversal is concurrently undertaken consistent with AHA\u002FASA guidelines.\n10. Patients who will undergo surgical evacuation consistent with AHA\u002FASA guidelines or local institutional guidelines are eligible unless surgical evacuation is being performed within 6 hours of initiation of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery will necessitate use of anesthetic agents which will confound the effect of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery\u002Fintervention was not used in the minimally invasive catheter evacuation followed by thrombolysis (MISTIE)\u002F Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR) trials, which required ICH patients to undergo a repeat CT scan after 6 hours to document absence of any hematoma expansion (with ≤5 mL hematoma growth) compared to a previous CT scan prior to any surgical intervention.\n11. Patients requiring external ventricular drainage consistent with AHA\u002FASA guidelines or local institutional guidelines are eligible.\n\nExclusion Criteria\n\n1. Time of symptom onset cannot be reliably assessed.\n2. Previously known neoplasms, arteriovenous malformation (AVM), or aneurysms.\n3. Intracerebral hematoma considered to be related to trauma.\n4. ICH located in infratentorial regions such as pons or midbrain (cerebellar ICH is not an exclusion criteria).\n5. Subject considered a candidate for immediate surgical intervention by the neurosurgery service.\n6. Pregnancy, parturition within previous 30 days, or active lactation.\n7. Any history of bleeding diathesis or coagulopathy except anticoagulant related ICH.\n8. Platelet count of less than 50,000\u002Fmm3.\n9. Known sensitivity to nicardipine or clevidipine.\n10. Patient's living will precludes aggressive ICU management.\n11. Patients with allergies to soybeans, soy products, eggs, or egg products.\n12. Defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia.\n13. Patients with severe aortic stenosis.","100 Years",{"count":551,"type":22},1000,"The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.",[554,29,555],"Intracerebral Hemorrhage","Hypertension",{"date":448,"type":37},{"date":558,"type":37},"2024-06-01",{"date":560,"type":22},"2028-07-30",{"name":562,"class":44},"Zeenat Qureshi Stroke Institute",16,{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":589},"100366007","phase-3-anticoagulation-for-new-onset-post-operative-atrial-fibrillation-after-cabg-100366007","NCT04045665","Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","PACES","Inclusion Criteria:\n\n* Patients of age ≥18 years who undergo isolated CABG for coronary artery disease\n* POAF that persists for \\>60 minutes or is recurrent (more than one episode) within 7 days after the index CABG surgery\n\nExclusion Criteria:\n\n* Clinical history of either permanent, persistent or paroxysmal atrial fibrillation\n* Any pre-existing clinical indication for long-term OAC\n* Any absolute contraindication to OAC\n* Planned use of post-operative dual antiplatelet therapy (DAPT)\n\n  a. This includes, but is not limited to, patients with recent PCI with drug-eluting or bare-metal stent.\n* Cardiogenic shock\n* Major perioperative complication\\* occurring between CABG and randomization\n\n  a. including, but not limited to, stroke, TIA, MI, major bleeding (BARC type 4 bleeding), severe sepsis, renal failure requiring dialysis, or need for reoperation due to bleeding (e.g. pericardial tamponade).\n* Concomitant left atrial appendage closure during CABG\n* Concomitant valve surgery during CABG or prior valve surgery (including aortic, mitral, tricuspid or pulmonary)\n* Concomitant mitral valve annuloplasty during CABG\n* Concomitant carotid artery endarterectomy during CABG\n* Concomitant aortic root replacement during CABG\n* Concomitant surgery for AF during CABG\n* Liver cirrhosis or Child-Pugh Class C chronic liver disease\n* Pharmacologic therapy with an investigational drug or device within 30-days prior to randomization or plan to enroll patient in an investigational drug or device trial during participation in this trial\n* Pregnancy at the time of randomization\n* Unable or unwilling to provide inform consent\n* Unable or unwilling to comply with the study treatment and follow-up\n* Existence of underlying disease that limits life expectancy to less than one year",{"count":572,"type":22},3200,[574],"PHASE3","The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.\n\nAll patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.",[508,29,577],"Bleeding",[579,580,581],"Anticoagulation","Antiplatelet Therapy","Post Operative Atrial Fibrillation",{"date":448,"type":37},{"date":584,"type":37},"2019-12-13",{"date":586,"type":22},"2026-08-31",{"name":588,"class":44},"Icahn School of Medicine at Mount Sinai",106,{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":603,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":77},"100644492","funcitonality-and-safety-of-a-knee-device-for-gait-rehabilitation-in-neurological-patients-100644492","NCT07670325","Funcitonality and Safety of a Knee Device for Gait Rehabilitation in Neurological Patients","Funzionalità e Sicurezza di un Dispositivo di Ginocchio Per Riabilitazione Della Deambulazione Con Pazienti Neurologici","AKO-R","Inclusion Criteria:\n\n* diagnosed stroke with fMRI\n* within 2 years from stroke event\n* FAC\\>= 3\n* height \\[1.5 - 2\\]m\n* weigth \\\u003C= 100 Kg\n\nExclusion Criteria:\n\n* MoCA\\\u003C18\n* Pregnancy\n* Implanted cardiac devices, such as pacemakers or implantable cardioverter defibrillators (ICDs)\n* Recent or current participation in research studies that, in the opinion of the Principal Investigator, may affect the subject's response to the study intervention\n* Severe aphasia\n* MAS=4",{"count":599,"type":22},20,[89],"This clinical investigation aims to evaluate the safety, feasibility, and preliminary performance of the AKO-R wearable robotic device for knee assistance during walking. The study involves participants performing treadmill and overground gait training under supervised conditions, with the device providing assistive torque to support movement. Clinical and functional outcomes are assessed using validated measurement tools, while additional data are collected to characterize user performance and interaction with the device. The study is designed as an exploratory investigation to gather evidence supporting the clinical use and further development of the device. Primary outcomes regards safety of the device and preliminary clinical benefit on gait symmetry.",[29],[604,605,339],"exoskeleton","robotics rehabilitation","2026-06-24",{"date":448,"type":37},{"date":609,"type":37},"2026-06-22",{"date":611,"type":22},"2026-11-30",{"name":613,"class":44},"Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna"]